Elevated release of sCD40L from platelets of diabetic patients by thrombin,glucose and advanced glycation end products

Abstract

The pro-inflammatory CD40/CD40L dyad participates in atherogenesis. Plasma levels of the soluble ligand (sCD40L) predict cardiovascular events and are elevated in diabetic patients. This study compared CD40/CD40L surface expression on platelets and T lymphocytes of diabetic and control subjects, and tested whether glucose and advanced glycation end products (AGEs) stimulate sCD40L release.

Constitutive and inducible surface expression of CD40/CD40L on platelets or T lymphocytes did not differ between diabetic patients (n=9) and controls (n=13). Platelets from diabetic patients contained higher intracellular CD40L than controls (p<0.05) and thrombin stimulated greater platelet sCD40L release in diabetic patients (15.11 ± 16.77 ng/ml) compared to controls (3.64 ± 2.03 ng/ml; p<0.05). Glucose and AGEs induced platelet sCD40L release and CD40L expression in mouse megakaryocytes.

This study demonstrates elevated CD40L content and inducible release from platelets of diabetic patients, and identifies glucose and AGEs as potential triggers of expression and release accounting for the elevated sCD40L plasma levels in these patients.

Keywords

CD40 ligand inflammation diabetes platelets

References

1. Schonbeck U , Libby P. CD40 signaling and plaque instability. Circ Res 2001;89:1092–103.

2. Lutgens E , Daemen MJ. CD40-CD40L interactions in atherosclerosis. Trends Cardiovasc Med 2002;12:27–32.

3. Mach F , Schonbeck U , Sukhova GK , Atkinson E , Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998;394:200–03.

4. Lutgens E , Gorelik L , Daemen MJ et al. Requirement for CD154 in the progression of atherosclerosis. Nat Med 1999;5:1313–16.

5. Schonbeck U , Sukhova GK , Shimizu K , Mach F , Libby P. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci USA 2000;97:7458–63.

6. Lutgens E , Cleutjens KB , Heeneman S , Koteliansky VE , Burkly LC , Daemen MJ. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Natl Acad Sci USA 2000;97:7464–9.

7. Aukrust P , Muller F , Ueland T et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999;100:614–20.

8. Schonbeck U , Varo N , Libby P , Buring J , Ridker PM. Soluble CD40L and cardiovascular risk in women. Circulation 2001;104:2266–8.

9. Heeschen C , Dimmeler S , Hamm CW et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003;348:1104–11.

10.

10. Varo N , de Lemos JA , Libby P et al. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 2003;108:1049–52.

11.

11. Blake GJ , Ostfeld RJ , Yucel EK et al. Soluble CD40 ligand levels indicate lipid accumulation in carotid atheroma: an in vivo study with high-resolution MRI. Arterioscler Thromb Vasc Biol 2003;23:e11–14.

12.

12. Marx N , Imhof A , Froehlich J et al. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 2003;107:1954–7.

13.

13. Varo N , Vicent D , Libby P et al. Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones. Circulation 2003;107:2664–9.

14.

14. Sheetz MJ , King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002;288:2579–88.

15.

15. Vlassara H , Palace MR. Diabetes and advanced glycation endproducts. J Intern Med 2002;251:87–101.

16.

16. Bucciarelli LG , Wendt T , Rong L et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci 2002;59:1117–28.

17.

17. Wendt T , Tanji N , Guo J et al. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol 2003;14:1383–95.

18.

18. Kunt T , Forst T , Harzer O et al. The influence of advanced glycation endproducts (AGE) on the expression of human endothelial adhesion molecules. Exp Clin Endocrinol Diabetes 1998;106:183–8.

19.

19. Falet H , Barkalow KL , Pivniouk VI , Barnes MJ , Geha RS , Hartwig JH. Roles of SLP-76, phosphoinositide 3-kinase, and gelsolin in the platelet shape changes initiated by the collagen receptor GPVI/FcR gamma-chain complex. Blood 2000;96:3786–92.

20.

20. Lecine P , Villeval JL , Vyas P , Swencki B , Xu Y , Shivdasani RA. Mice lacking transcription factor NF-E2 provide in vivo validation of the pro-platelet model of thrombocytopoiesis and show a platelet production defect that is intrinsic to megakaryocytes. Blood 1998;92:1608–16.

21.

21. Henn V , Slupsky JR , Grafe M et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591–4.

22.

22. Wautier MP , Massin P , Guillausseau PJ et al. N(carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetic patients. Diabetes Metab 2003;29:44–52.

23.

23. Andre P , Nannizzi-Alaimo L , Prasad SK , Phillips DR. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 2002;106:896–9.

24.

24. Appay V , Rowland-Jones SL. RANTES: a versatile and controversial chemokine. Trends Immunol 2001;22:83–7.

25.

25. Kingsley K , Huff JL , Rust WL , Carroll K , Martinez AM , Fitchmun M , Plopper GE. ERK1/2 mediates PDGF-BB stimulated vascular smooth muscle cell proliferation and migration on laminin-5. Biochem Biophys Res Commun 2002;293:1000–06.